WO2006079999A2 - Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda - Google Patents

Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda Download PDF

Info

Publication number
WO2006079999A2
WO2006079999A2 PCT/IB2006/051080 IB2006051080W WO2006079999A2 WO 2006079999 A2 WO2006079999 A2 WO 2006079999A2 IB 2006051080 W IB2006051080 W IB 2006051080W WO 2006079999 A2 WO2006079999 A2 WO 2006079999A2
Authority
WO
WIPO (PCT)
Prior art keywords
human
ht2a
nmda
nmda antagonist
receptors
Prior art date
Application number
PCT/IB2006/051080
Other languages
English (en)
Other versions
WO2006079999A3 (fr
Inventor
Frederik H. Barth
Original Assignee
Barth Frederik H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barth Frederik H filed Critical Barth Frederik H
Priority to PCT/IB2006/051080 priority Critical patent/WO2006079999A2/fr
Publication of WO2006079999A2 publication Critical patent/WO2006079999A2/fr
Publication of WO2006079999A3 publication Critical patent/WO2006079999A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Il a été découvert que l'administration, à un être humain, d'un agoniste de 5-HT2A hallucinogène en combinaison avec un antagoniste de NMDA induisait un état nouveau et particulier du psychisme humain. Cet état psychique est non psychotique et bénin. L'induction de cet état nouveau et particulier du psychisme humain peut être utilisé à des fins thérapeutiques, récréatives et à d'autres fins utiles.
PCT/IB2006/051080 2006-04-09 2006-04-09 Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda WO2006079999A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/051080 WO2006079999A2 (fr) 2006-04-09 2006-04-09 Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/051080 WO2006079999A2 (fr) 2006-04-09 2006-04-09 Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda

Publications (2)

Publication Number Publication Date
WO2006079999A2 true WO2006079999A2 (fr) 2006-08-03
WO2006079999A3 WO2006079999A3 (fr) 2007-04-26

Family

ID=36740888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/051080 WO2006079999A2 (fr) 2006-04-09 2006-04-09 Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda

Country Status (1)

Country Link
WO (1) WO2006079999A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (fr) * 1990-10-15 1992-04-30 Pfizer Inc. Derives d'indole
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO2006042249A2 (fr) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methodes et compositions de traitement de la douleur de migraine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (fr) * 1990-10-15 1992-04-30 Pfizer Inc. Derives d'indole
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO2006042249A2 (fr) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methodes et compositions de traitement de la douleur de migraine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FARBER NURI B ET AL: "Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity" NEUROPSYCHOPHARMACOLOGY, vol. 18, no. 1, January 1998 (1998-01), pages 57-62, XP002396767 ISSN: 0893-133X *
WEST WILLIAM B ET AL: "Antagonism of a PCP drug discrimination by hallucinogens and related drugs" NEUROPSYCHOPHARMACOLOGY, vol. 22, no. 6, June 2000 (2000-06), pages 618-625, XP002396768 ISSN: 0893-133X cited in the application *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10947257B2 (en) 2017-10-09 2021-03-16 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10954259B1 (en) 2017-10-09 2021-03-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11149044B2 (en) 2017-10-09 2021-10-19 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11180517B2 (en) 2017-10-09 2021-11-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11447510B2 (en) 2017-10-09 2022-09-20 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11505564B2 (en) 2017-10-09 2022-11-22 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11629159B2 (en) 2017-10-09 2023-04-18 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11851451B2 (en) 2017-10-09 2023-12-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11939346B2 (en) 2017-10-09 2024-03-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11738035B2 (en) 2019-04-17 2023-08-29 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Also Published As

Publication number Publication date
WO2006079999A3 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
Hintzen et al. The pharmacology of LSD
Kosten Pharmacotherapeutic interventions for cocaine abuse matching patients to treatments
White et al. Pharmacological properties of ketamine
JP2010535801A5 (fr)
Hosobuchi et al. Tryptophan loading may reverse tolerance to opiate analgesics in humans: a preliminary report
TW201011007A (en) Treatment for neurological and mental disorders
Semenova et al. Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine
Duque et al. Relative potency of ketamine and S (+)‐ketamine in dogs
Bourbeau Exercise and neural adaptations: Designing a novel treatment for alcohol addiction
Gupta et al. Relationship between endogenous opioid function and opioid analgesic adverse effects
Ahmadi et al. Homicidal patient with major depressive disorder companion with opium dependence: A new arcade
Uddin et al. Amphetamines: Potent recreational drug of abuse
WO2006079999A2 (fr) Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda
CN101495121A (zh) 用于治疗物质滥用和物质依赖的方法
Rivera-García et al. The Resurgence of Hallucinogen Drugs in Clinical Research
Holze et al. Serotonergic Psychedelics–a Comparative review Comparing the Efficacy, Safety, Pharmacokinetics and Binding Profile of Serotonergic Psychedelics
JP2008536921A (ja) アルコール及び／又は刺激物質の乱用を治療するための選択的塩素イオンチャネルモジュレーターの使用
CN116916903A (zh) 墨斯卡林和墨斯卡林类似物（scalines）辅助心理治疗的作用
CN109666055A (zh) 调节中枢神经治疗抑郁症的化合物及其用途
Alikhani et al. The effects of exercise on the mental health
US20020032197A1 (en) Methods and compositions for using moclobemide
Nagal et al. Parkinson’s Disease: Diagnosis, Therapeutics & Management
Moosa-Battey The renaissance of psychedelic-assisted psychotherapy
He et al. Drug Therapy
Venkataraman et al. Drug use and associated neuropsychiatric conditions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06727863

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06727863

Country of ref document: EP

Kind code of ref document: A2